Esomeprazole dosing

Pro Research Analysisby

Searched over 200M research papers for "esomeprazole dosing"

Analyzed relevant papers

Esomeprazole Dosing: Standard, Low, and Novel Formulations

Standard Esomeprazole Dosing for Acid-Related Disorders

Esomeprazole is commonly prescribed in 20 mg or 40 mg doses once daily for the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and for the prevention of ulcers in patients taking low-dose aspirin. Both 20 mg and 40 mg daily doses have been shown to significantly reduce the risk of peptic ulcer development in at-risk patients, with similar safety and tolerability profiles .

Dual Delayed-Release (DR) and Immediate-Release (IR) Formulations

Recent studies have evaluated new dual delayed-release (DR) and immediate-release (IR) formulations of esomeprazole. These formulations aim to provide more sustained or faster acid suppression compared to conventional enteric-coated (EC) esomeprazole.

Dual DR formulations (such as Esomezol DR and YYD601) maintain plasma esomeprazole levels for a longer period, resulting in similar overall acid suppression as conventional EC formulations, but with a tendency for better night-time acid control 124.
IR formulations, which combine esomeprazole with sodium bicarbonate, offer a faster onset of action while maintaining similar overall acid suppression and safety compared to EC formulations 89.

Low-Dose Esomeprazole for Gastritis and Mild Acid Disorders

Low-dose esomeprazole (10 mg daily) has been studied for the treatment of gastritis and mild acid-related symptoms. Studies show that 10 mg daily provides acid suppression comparable to famotidine 20 mg, a commonly used H2 receptor antagonist, and is well tolerated 56. The 10 mg dose is less effective than 20 mg for maintaining gastric pH above 4, but still offers a viable option for mild cases .

Dosing Considerations: Food, Genetics, and Special Populations

Food intake can reduce esomeprazole absorption by about 33%, so it is generally recommended to take esomeprazole before meals for optimal effect .
Genetic differences, especially in the CYP2C19 enzyme, can affect esomeprazole metabolism and acid suppression, with poor metabolizers experiencing higher drug exposure and greater acid suppression .
In veterinary medicine, once-daily dosing (0.5–1 mg/kg) is effective in most dogs, but some may require twice-daily dosing to achieve target acid suppression .

High-Dose Esomeprazole in Special Situations

Very high doses of esomeprazole (e.g., 80 mg bolus followed by continuous infusion) are being investigated for anti-inflammatory effects in critical care settings such as sepsis, but these doses are much higher than those used for standard acid suppression and are not routine in general practice .

Conclusion

Esomeprazole is effective and well tolerated at standard doses of 20 mg or 40 mg once daily for acid-related disorders, with both conventional and novel DR/IR formulations providing similar acid suppression. Low-dose esomeprazole (10 mg) is a suitable option for mild symptoms or gastritis. Dosing should consider meal timing and individual patient factors such as genetics. New formulations may offer advantages in onset or duration of acid suppression, especially for night-time symptoms.

Sources and full results

Most relevant research papers on this topic

Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects.

The dual delayed-release formulation of esomeprazole (Esomezol DR) provides longer and higher gastric acid inhibition compared to the conventional enteric-coated formulation, potentially relieving nocturnal acid-related symptoms.

RCT

2023·

5citations

·Hyun Chul Kim et al.

Pharmacokinetics and Pharmacodynamics of YYD601, a Dual Delayed-Release Formulation of Esomeprazole, Following Single and Multiple Doses in Healthy Adult Volunteers Under Fasting and Fed Conditions

YYD601 30 mg has a comparable effect on gastric acid inhibition as conventional esomeprazole 40 mg after once daily oral administration, and is safe and well-tolerated in healthy adults.

RCTRigorous Journal

2022·

3citations

·H. Lee et al.

Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)

Once-daily esomeprazole 40 mg or 20 mg significantly reduces the occurrence of peptic ulcers in patients at risk for ulcer development who are taking low-dose acetylsalicylic acid.

RCTLarge Human TrialVery Rigorous JournalHighly Cited

2011·

136citations

·J. Scheiman et al.

A Pharmacokinetic/Pharmacodynamic Study of Esomeprazole Comparing a Dual Delayed-Release Formulation (YYD601) to a Conventional Formulation Following Multiple Administrations in Healthy Adult Subjects

YYD601 20 mg provides comparable gastric acid suppression to conventional esomeprazole 20 mg, with a greater tendency to suppress acid at night, and is a safe and well-tolerated alternative.

RCT

2025·

0citations

·H. Lee et al.

Pharmacodynamics Between a Dual Delayed-Release Formulation of Low-Dose Esomeprazole and Famotidine in Healthy Korean Subjects.

A dual delayed-release esomeprazole (10 mg) showed effective gastric acid secretion suppression compared to famotidine (20 mg) with comparable safety and tolerability in healthy Korean subjects.

RCT

2024·

0citations

·Young-Sim Choi et al.

Comparison of the acid suppression effects between low-dose esomeprazole and famotidine in healthy subjects.

Low-dose esomeprazole 10 mg shows comparable pharmacodynamic properties to famotidine, suggesting it could be a potential treatment option for gastritis.

RCT

2023·

2citations

·Ha-Yeon Kim et al.

Pharmacodynamics of 2 dosages of orally administered esomeprazole in client‐owned, healthy dogs: A prospective, crossover study

Both q24h esomeprazole doses effectively raise intragastric pH in dogs, but 33% require q12h dosing to reach pH goals.

RCTAnimal Study

2024·

1citation

·Abby Ostronic et al.

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male

IR-ESO provides rapid, safe, and sustained gastric acid suppression, similar to esomeprazole 20 mg, with a faster onset and no significant differences in adverse events.

RCTRigorous Journal

2019·

12citations

·Dasohm Kim et al.

Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial

Immediate-release capsules containing esomeprazole 20 mg and sodium bicarbonate 1100 mg effectively inhibit gastric acid secretion, with pharmacokinetics and pharmacodynamics influenced by CYP2C19 genotypes.

RCTRigorous Journal

2021·

6citations

·Shan Jing et al.

High dose esomeprazole as an anti-inflammatory agent in sepsis: Protocol for a randomized controlled trial.

High dose esomeprazole may reduce organ dysfunction in patients with sepsis or septic shock by regulating immune responses and improving clinical outcomes.

RCTLarge Human Trial

2023·

4citations

·G. Monti et al.

Try another search

spacecraft design

losartan drug interactions

mars surface composition

dietary factors that increase HDL cholesterol

improving blood circulation

banana and cholesterol levels